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Introduction
Concurrent with the widespread use of population based 
screening programs, there are more than 42,000 newly 
diagnosed cases of rectal cancer each year (1). Radical 
surgical resection of both the primary tumor and the 
draining lymph node basin (by either low anterior or 
abdominoperineal resection) remains the corner stone of 
curative therapy in rectal cancer of all stages. However, 
the staging accuracy of endorectal ultrasound (ERUS) and 
pelvic magnetic resonance imaging (MRI) has led some 
to question the necessity of a major surgical resection for 
early T-stage cancers when the entire tumor burden could 
(theoretically) be resected complete by transanal excision. 
The optimal treatment of early rectal adenocarcinoma 
remains debatable, although most surgeons recommend 
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and an increased post-operative surveillance regimen to preserve a perceived increased quality of life.
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radical resection for T2 lesions.
The surgical approach to rectal cancer has evolved 
continually over the last 100 years. The trend towards 
less invasive surgical procedures is clear: from the initial 
attempts at trans-sacral resection, to the popularization of 
universal abdominoperineal resection (the Miles procedure), 
followed by acceptance of low anterior resection (greatly 
facilitated by surgical stapling technology). Transanal, local 
excision of early cancers is the logical extension of this 
trend. At present, radical resection with total mesorectal 
excision (TME) is the surgical standard of care for rectal 
cancer. This approach completely removes the primary 
tumor and draining lymph node basin, allowing accurate 
and complete pathological staging. Radical resection with 
TME is also fully curative in patients with node-negative 
and early T-stage cancers. However, radical resection carries 
a 2-3% perioperative mortality rate and 20-30% overall 
complication rate (2). Additionally, long-term complications 
such as sexual impotence, decreased fecundity in women, 
alterations in bowel function (e.g., the anterior resection 
syndrome), and the potential for a permanent ostomy all 
adversely affect quality of life (2-5).
In contrast ,  local  excis ion avoids the common 
complications associated with a major operation allowing 
for decreased anesthesia, minimal fluid shifts and blood 
loss in combination with a shorter hospital stay and 
quicker recovery. But the decreased invasiveness comes 
at the expense of an oncologically incomplete surgery. 
Advocates for local excision assert that failure due to occult 
mesorectal lymph node metastases is potentially treatable 
with salvage total mesorectal excision. Although current 
imaging modalities have improved, some patients will not 
be accurately staged. Only after presenting with a local 
failure will they receive appropriate adjuvant therapy. For 
this reason, local excision mandates a strict adherence to 
an intense post-operative surveillance schedule extending 
beyond 5 years to detect any recurrence.
Appropriate patient and tumor selection remain a major 
obstacle to transanal excision of rectal cancer, although 
advances in understanding tumor biology may improve 
this process. There are no widely accepted guidelines for 
utilizing local excision. In general, it is reserved for tumors 
isolated to the submucosa (T1) that are well to moderately 
differentiated with low-risk histopathological features. 
Lymphovascular invasion, perineural invasion, and mucinous 
components are considered high-risk characteristics, and 
local excision should be avoided due to an increased rate 
of lymph node metastasis. In addition, tumors should 
ideally be <3 cm in size with a clear margin, occupy less 
than 1/3 of the circumference of the bowel and be mobile/
nonfixed (6). Despite these stringent inclusion criteria, local 
excision continues to be plagued with a high recurrence 
rate (Table 1). The goal for the treatment of early (T1 and 
T2) rectal cancer is to optimize oncologic control while 
minimizing the long-term impact of treatment on quality of 
life (7). This paper will review the data for both T1 and T2 
adenocarcinomas, as well some of the promising surgical and 
combined modalities for treating these early cancers.
Transanal excision for T1 adenocarcinoma
Cancer biology differs substantially throughout the lower 
gastrointestinal tract, with a predisposition for early lymph 
node spread in the rectum compared to the proximal 
Table 1 Appropriate tumor selection for local excision
Characteristics Favorable Unfavorable
1 Well differentiated Poorly differentiated
2 Moderately differentiated
3 No lymphovascular invasion Lymphovascular invasion
4 No perineural invasion Perineural invasion
5 No mucinous components Evidence of mucin production
6 Invasion to level sm1 and sm2 Invasion to level sm3
<3 cm in size >3 cm in size
<1/3 the circumference of the rectal wall >1/3 the circumference of the rectal wall
<10 cm from the anal verge >10 cm from the anal verge
7 Mobile lesion Fixed lesion
sm, submucosa; cm, centimeter.
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colon (4). Although limited to the bowel submucosa, T1 
rectal cancer has a 13-25% rate of occult lymph node 
spread compared to only 3-8% in the colon (4,8). While it’s 
not uncommon to retrieve 1 or 2 lymph nodes along with 
a full-thickness transanal resection, the nodal basin is not 
sufficiently staged by local excision alone. Despite lingering 
concerns about the adequacy of a transanal excision, a 
paradoxical increase in the use of local excision for T1 
tumors occurred in the United States between 1989-2003 (9). 
Subsequently, several authors have cautioned against local 
excision, citing excessively high local recurrence rates and 
worse oncological outcomes (see below), possibly due to 
lack of rigorous patient and tumor selection.
Most neoplasms less than 10 cm from the anal verge 
can be resected transanally. Local excision results in a full-
thickness specimen including some mesorectal fat. At least 
1 cm circumferential mucosal margins should be obtained. 
The specimen is usually pinned to corkboard or sponge 
by the surgeon to avoid confusion over orientation and 
specimen contraction from soaking in Formalin. The defect 
in the bowel wall is subsequently closed, typically in a 
transverse manner to prevent restriction of the rectal lumen. 
Patients perform a full mechanical bowel preparation prior 
to the surgery, but recovery postoperatively is rapid, with 
early resumption of regular diet and activity and minimal 
discomfort.
ERUS and/or pelvic MRI are mandatory for the preoperative 
staging of rectal cancers. ERUS is more sensitive in 
distinguishing early bowel invasion of the primary, while 
MRI is superior at evaluating mesorectal lymph nodes 
and the circumferential resection margin. The utility of 
combining ERUS and MRI to direct surgical therapy has 
also been explored by various investigators (10). Recently 
though, several studies have reported a significantly lower 
sensitivity rate (48-54%) of ERUS for detecting early 
T1 cancer as compared to higher staged lesions (11,12). 
The success of transanal excision relies on the accuracy of 
preoperative clinical staging as it fails to address possible 
occult lymph node metastasis. Presumably the higher 
regional recurrence rate following local excision is at least 
in part explained by a failure of preoperative imaging 
modalities to detect micro-metastatic disease within 
mesorectal lymph nodes.
The literature on local recurrence rates after transanal 
excision for T1 rectal cancer is comprised mostly of 
retrospective studies containing a heterogeneous population 
of high and low risk lesions (Table 2). Despite the differences 
between the series, the type of surgery (transanal excision 
Table 2 Outcomes after local excision vs. radical surgery for T1 adenocarcinoma of the rectum
Series Surgery performed N High grade (%) LR (%) DR (%) OS (%) DFS (%) Median F/U (mo)
Local excision
Garcia-Aguilar et al., 1999 TAE 55 0 16.0 4.0 82 77 52
Paty et al., 2002 TAE 74 15.0 17.0 – 74 – 120
Gopaul et al., 2004 TAE 32 – 13.0 – – – 37
Bentrem et al., 2005 TAE 151 9.0 15.0 12.0 89 93 60
Endreseth et al., 2005 TAE 35 1.0 12.0 0 70 64 60
Madbouly et al., 2005 TAE 52 0 23.0 12.0 75 70 55
You et al., 2007 LE-ANS 601 5.3 8.2 3.6 77 93 60
Nash et al., 2009 TAE 137 52.0 19.0 19.0 69 83 59
Doornebosch et al., 2010 TEM 88 6.0 21.0 8.0 – – 36
Radical resection
Bentrem et al., 2005 RR-NOS 168 10.0 3.0 3.0 93 97 60
Endreseth et al., 2005 LAR/APR 256 15.0 6.0 7.0 80 77 60
You et al., 2007 RR-NOS 493 7.5 4.3 2.6 82 97 60
Nash et al., 2009 LAR/APR 145 – – – 85 94 77
TAE, transanal excision; TEM, transanal endoscopic microsurgery; LE-ANS, local excision, approach not specified; LAR, low 
anterior resection; APR, abdominoperineal resection; RR-NOS, radical resection, not otherwise specified; LR, local recurrence; 
DR, distant recurrence; OS, overall survival; DFS, disease free survival; F/U, follow-up; mo, months.
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vs. radical resection) remains a constant predictor of local 
recurrence, with radical resection always maintaining a 
lower local recurrence rate. The gap between the treatment 
modalities does narrow though when stratifying tumors 
by both clinical and pathologic criteria. Blumberg and 
colleagues demonstrated that excluding high-risk factors 
(lymphovascular invasion, mucin production, poor 
differentiation) and applying strict clinical factors (distance 
from anal verge and size) could decrease the lymph node 
metastases rate from 16% to 7% (2.3 fold) (5). Kikuchi et al. 
showed that not all T1 tumors behave in the same manner, 
and their invasiveness stems from the level of submucosal 
infiltration. For tumors only slightly invading the 
submucosa (sm1) there were no nodal metastases observed, 
as opposed to tumors invading the deepest one-third of the 
submucosa (sm3) that had a 25% rate of metastases (13). 
Sm3 depth of invasion has been confirmed by other authors 
as a contraindication for local excision (8). Greenberg et al. 
provided long-term follow-up on the prospective CALGB 
8984 study of local excision of T1 rectal cancer (14). The 
authors found a local recurrence rate of only 8% at 7.1 years 
median follow-up using stringent selection criteria. Others 
have confirmed that oncological outcomes in prospective 
series seem improved relative to the larger retrospective 
reports, reinforcing the importance of strict attention to 
patient and tumor selection (2).
Although there is an increased local recurrence rate 
between the surgical modalities, this has failed to translate 
into a survival benefit. After 5 years, there is an overall 
survival rate of 70-89% vs. 77-97% and disease free survival 
rate of 64-93% vs. 80-93% in the transanal excision and 
radical resection groups, respectively (2,4). Conversely, 
the similar survival rates may reflect an inadequate follow-
up time. During 10 years of follow-up by Nash et al., the 
authors found a similar overall survival in the first 4 years 
after diagnosis but an increased rate of cancer-related death 
between 4-8 years (peak period of cancer recurrence) in the 
transanal excision group. Only after 9 years did death from 
other causes dominate in the transanal excision group (12). 
Patients undergoing local excision must be committed to a 
long-term follow-up schedule to detect recurrences.
If high-risk features are identified in the original 
pathologic specimen, an immediate radical resection should 
be performed. This does not compromise outcomes and 
has a 94% disease free survival rate at 5 years (15). In this 
manner, the transanal excision may be viewed as a “large 
biopsy”, the results of which may direct further immediate 
surgery. However, the aggressive use of salvage surgery 
after identifying a local recurrence can still allow for an 
R0 resection to be accomplished in a majority of cases 
(77%) (4). With routine post-operative surveillance, the 
detection rate is up to 88% with proctoscopy and ERUS 
alone, although most centers also utilize either computed 
tomography (CT) or MRI (16). Salvage surgery, though, 
comes with the cost of increased morbidity compared to 
an initial radical resection and may require multivisceral 
resection and an ostomy in up to 43% (4). After salvage 
surgery, the 5-year overall survival is significantly decreased 
to 43-56.2% compared to those without a recurrence 
(3,4). The relatively poor outcomes following salvage 
surgery emphasize the importance of the appropriate initial 
treatment of early rectal cancer.
Transanal excision for T2 adenocarcinoma
Similar to T1 tumors, there was almost a fifty percent 
increase across the US between 1989-2003 in the use of local 
excision to treat T2 rectal cancer (12% to 21%) (7). While 
local excision is now generally an acceptable treatment of 
T1 tumors, there is a growing concern about extending its 
application to T2. Transanal excision of T2 tumors carries a 
nearly double local recurrence rate compared to T1 lesions, 
ranging from 13-30% for the more advanced primary 
lesions (Table 3). The higher local recurrence rate is likely 
due to the increased occult nodal metastasis rate of 28-
38% (17). Conversely, radical resection has only a slightly 
increased rate of local recurrence at 7.2% compared to that 
for T1 tumors (9). This finding emphasizes both the staging 
and therapeutic benefits of total mesorectal excision.
The increased invasiveness and locoregional metastatic 
potential of T2 tumors is also reflected in the decreased 
overall survival, and the difference is increased for patients 
undergoing local excision as compared to radical resection. 
In the nationwide cohort study by You et al., there was 
a significant difference in overall survival (68% vs. 77%, 
P=0.01) between local excision and radical resection (9). 
This was strongly impacted, though, by nononcologic 
factors related to the patient [age (>75) and multiple 
comorbidities (>2)] rather than the type of surgery. The 
disease-free survival did not differ (90% vs. 92%, P=0.95) 
at 5 years, likely due to early death by other non-cancer 
related causes (9). Given the advanced age and poor health 
of this study population, they may not have been candidates 
for a radical resection. Nevertheless, the 90% disease free 
survival in the radical resection group demonstrates the 
effectiveness of the procedure in providing a cure.
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At present, it seems imprudent to locally excise T2 rectal 
cancers in fit patients (11). Local excision offers a moderate 
chance of cure and is reasonable for patients in whom major 
surgery is contraindicated due to medical comorbidities.
Transanal excision after neoadjuvant 
chemoradiation
Neoadjuvant chemoradiation has consistently demonstrated 
the ability to reduce local recurrence rates and downstage 
primary tumors in select patients with rectal cancers 
(18,19). This has sparked interest in its application in early 
rectal cancer (20). Most of the neoadjuvant and adjuvant 
scheduled in the literature used a similar of radiation dose (50.4-
54 Gy), and all chemotherapy regimens are 5-fluoruracil (5-
FU) based. As shown in Table 4, tumor downstaging and 
downsizing has been demonstrated in 51-64% and 26-100% 
of T2 rectal cancers, respectively (20,21). It is important to 
note that complete clinical response only translates to a 30-
60% pathologically complete response for which there is 
minimal disease recurrence (20-22). Lezoche et al. reported 
that overall recurrences occurred primarily in the low 
response and non-responder groups, at rates of 12% after 
local excision and 10% after radical resection (21). A more 
aggressive surgical approach is indicated for these patients, 
as an incomplete response likewise may exist in the regional 
lymph nodes (22). Using a neoadjuvant regimen consisting 
of 4,500 cGy in 25 fractions of radiation over three fields 
with a boost of 540 cGy to the tumor in conjunction with 
a continuous infusion of 300 mg m–2 day–1 of 5-FU on days 
of radiation over a 5-week course, Nair et al. noted that the 
overall survival was not significantly different between the 
local excision group and radical resection group (72% vs. 
80%, P=0.61) (22). In the transanal excision of T2 rectal 
cancer, neoadjuvant therapy has shown favorable short-
term and similar long-term oncological outcomes to radical 
resection.
The improved oncologic benefits  of  combined 
chemoradiation therapy do not come without a price. 
Chemo-radiation increases the rate of post-operative 
Table 3 Outcomes after local excision vs. radical surgery for T2 adenocarcinoma of the rectum
Series Surgery performed N High grade (%) LR (%) DR (%) OS (%) DFS (%) Median F/U (mo)
Local excision
Garcia-Aguilar et al., 1999 TAE 27 0 30.0 7.0 63 55 58
Paty et al., 2002 TAE 51 – 28.0 – 75 – 120
Gopaul et al., 2004 TAE 25 – 24.0 – – – 37
You et al., 2007 LE-ANS 164 13.4 13.0 5.0 68 90 60
Radical resection
You et al., 2007 RR-NOS 866 7.9 7.2 7.7 77 92 60
TAE, transanal excision; TEM, transanal endoscopic microsurgery; LE-ANS, local excision, approach not specified; RR-NOS, 
radical resection, not otherwise specified; LR, local recurrence; DR, distant recurrence; OS, overall survival; DFS, disease free 
survival; F/U, follow-up; mo, months.
Table 4 Outcomes after neoadjuvant chemoradiation therapy for T2 adenocarcinoma of the low rectum
Series Surgery performed N Chemo vs. radiation LR (%) DR (%) OS (%) DFS (%) Median F/U (mo)
Local excision
Nair et al., 2008 TAE 10 Both 10 10 81 – 60
Lezoche et al., 2012 TEM 50 Both 8 4 72 89 115
Perez et al., 2013 TEM 18 Both 14 19 85 68 15
Radical resection
Lezoche et al., 2012 Lap LAR 50 Both 6 4 80 94 115
TAE, transanal excision; TEM, transanal endoscopic microsurgery; Lap LAR, laparoscopic low anterior resection; LR, local 
recurrence; DR, distant recurrence; OS, overall survival; DFS, disease free survival; F/U, follow-up; mo, months.
350 Heafner and Glasgow. Review of local excision for early (T1 and T2) rectal cancer
© Pioneer Bioscience Publishing Company. All rights reserved. J Gastrointest Oncol 2014;5(5):345-352www.thejgo.org
complications;  however,  most of  these are minor 
complications (91%) that can be managed without 
additional surgery (20). The most common side effects were 
gastrointestinal, dermatologic, and hematologic.
The use of neoadjuvant therapy for T2 rectal cancer 
should not be over utilized, though, as radical surgery alone 
provides an adequate treatment for T2 N0 disease. It’s 
role may be to downsize and downstage borderline T2-T3 
tumors. Local excision may then be utilized to determine 
the pathological response to the chemoradiation. If there is 
only a partial response and tumor still remains, immediate 
radical resection should be performed. It is the authors’ 
current practice to determine surgical treatment prior to 
initiating neoadjuvant therapy.
Transanal endoscopic microsurgery for T1 and 
T2 adenocarcinoma
Transanal endoscopic microsurgery (TEM) for local 
excision of rectal adenomas was originally described by 
Dr. Buess of Germany in 1983. Although the technique 
and instruments have undergone refinement over the 
past 30 years, the surgical principles have remained the 
same. The patient is positioned on the table (lithotomy, 
prone jackknife, lateral decubitus) such that the tumor is 
in the posterior position. A specialized set of instruments 
including a 40 mm rectoscope and laparoscopic style tools 
are required, although newer minimally invasive equipment 
can be adapted for transanal use (e.g., transanal minimally 
invasive surgery). After appropriate insufflation of the 
rectum, the tumor is visualized and a 1 cm circumferential 
margin marked with electrocautery. A full thickness excision 
is then performed, the specimen oriented on the back table 
and the resulting defect closed transversely with absorbable 
sutures.
TEM is similar to transanal excision in that patients 
can expect a short (1-2 day) hospital stay, decreased 
complications and quicker recovery. The complication 
rate after TEM is <5% and includes bleeding, rectovaginal 
fistula, transient incontinence to gas and stool, and transient 
urinary retention (23). There are several key differences, 
though, between the two operations. TEM often requires 
a general anesthetic to perform the procedure, which may 
be contraindicated in patients with severe cardiopulmonary 
disease, opposed to spinal or local anesthesia for traditional 
transanal excision. The superior visualization and 
instrumentation afforded by TEM relative to traditional 
transanal excision often permits en bloc specimen 
removal, thus avoiding piecemeal resection. This allows 
for an increased rate of R0 resection and a more accurate 
histological evaluation of the circumferential and deep 
margin.
TEM is the gold-standard operation for the resection of 
rectal adenomas, but its use as a curative option for rectal 
carcinoma is debatable. Despite having a significantly 
decreased rate of R1 resection between TEM and 
traditional transanal excision (2% vs. 16%) (24), achieving 
an R0 resection did not prevent local recurrence (16). 
Even when stratifying to low-risk T1 tumors, there is still 
a 17% local recurrence rate after TEM (16). There was no 
significant difference in the 5-year recurrence rate between 
T1 and T2 tumors removed by either local excision 
technique (21% vs. 33%, P=0.07) (24). Due to the high rate 
of local recurrence in low-risk patients with even an R0 
resection, improving criteria for tumor resection by TEM is 
of major importance.
TEM suffers from the same shortcomings as traditional 
transanal excision in being unable to adequately stage the 
pelvis. Using the same post-operative surveillance schedule 
as transanal excision, most recurrences can be detected early 
enough to allow for salvage surgery. Short term follow-
up after salvage surgery shows a cancer-related survival of 
79% at 1 year and 58% at 3 years, which is comparable 
to transanal excision (16). Between the two local excision 
modalities, the 5-year disease free survival (85% vs. 70%, 
P=0.146) and overall survival (80% vs. 66%, P=0.119) were 
similar across both T1 and T2 lesions (24).
In summary, TEM provides better visualization of 
the tumor allowing for a more proficient operation to be 
performed. However, this has not translated to improved 
local recurrence or overall survival compared to traditional 
transanal excision. While some authors advocate for TEM 
as the treatment of choice for local excision, patient and 
tumor-specific features remain paramount regardless of the 
surgical approach. Further studies are needed examining 
the relative effectiveness of TEM compared to traditional 
transanal excision.
Surveillance following local excision
Following local excision, a long-term surveillance schedule 
is mandatory to identify recurrences that are potentially 
resectable and metachronous lesions. Although centers 
vary slightly in their follow-up regimen, each consists 
of at least a semiannual history and physical exam, 
carcinoembryonic antigen (CEA), and proctoscopy in 
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conjunction with annual imaging (CT or MRI) (4,6,11). 
There has been an increased trend in the combined use 
of CT/MRI with ERUS postoperatively to increase the 
sensitivity in detecting locoregional recurrences. It is the 
authors’ current practice to perform a history and physical 
examination every 3-6 months for the first 2 years and then 
annually after. A baseline CEA is obtained prior to surgery 
and then followed at every appointment. To detect mucosal 
recurrences, a digital rectal exam and proctoscopy or flexible 
sigmoidoscopy are performed every 3-6 months for 2 years 
and then yearly after. This is alternated with ERUS every 
6 months to evaluate for lymph node metastases. Finally, a 
CT or MRI is obtained annually to detect local or distant 
recurrences. Most surveillance schedules only extend out 
to five years, but given the propensity for late recurrences, 
long-term follow-up after local excision should be pursued.
Conclusions
The management of early (T1 and T2) rectal cancer must 
be individualized to each patient’s expectations of quality 
and quantity of life. Even in the lowest risk patients, 
transanal excision is inferior to radical resection from an 
oncologic standpoint due to inadequate local control and 
staging of the pelvis leading to an increased local recurrence 
rate. However, with informed consent, patients may be 
willing to accept a higher failure rate and an increased post-
operative surveillance regimen to preserve a perceived 
increased quality of life. Accurate and appropriate patient 
selection for local excision hinges on preoperative imaging 
techniques and sound histopathology. Local excision 
remains an acceptable option in well-to-moderately 
differentiated T1 rectal cancers with favorable histological 
features, provided the surgeon can obtain clear margins. 
Future investigations to improve preoperative clinical and 
pathological staging may improve patient selection and 
decrease local recurrence.
Acknowledgements
Funding: The authors received no financial support for the 
research and/or authorship of this article.
Disclosure: The authors declare no conflicts of interest with 
respect to the authorship and/or publication of this article. 
The opinions and assertions contained herein are the 
private views of the authors and are not to be construed as 
official or reflecting the views of the Department of the Air 
Force or Department of Defense.
References
1. Stamos MJ, Murrell Z. Management of early rectal T1 and 
T2 cancers. Clin Cancer Res 2007;13:6885s-9s.
2. Endreseth BH, Myrvold HE, Romundstad P, et al. 
Transanal excision vs. major surgery for T1 rectal cancer. 
Dis Colon Rectum 2005;48:1380-8.
3. Madbouly KM, Remzi FH, Erkek BA, et al. Recurrence 
after transanal excision of T1 rectal cancer: should we be 
concerned? Dis Colon Rectum 2005;48:711-9; discussion 
719-21.
4. Bentrem DJ, Okabe S, Wong WD, et al. T1 
adenocarcinoma of the rectum: transanal excision or 
radical surgery? Ann Surg 2005;242:472-7; discussion 
477-9.
5. Blumberg D, Paty PB, Guillem JG, et al. All patients with 
small intramural rectal cancers are at risk for lymph node 
metastasis. Dis Colon Rectum 1999;42:881-5.
6. Network NCC. National Comprehensive Cancer 
Network: NCCN Clinical Practice Guideline in 
Oncology: Rectal Cancer- Version 3.2014. Fort 
Washington, PA: 2014. 
7. Stitzenberg KB, Sanoff HK, Penn DC, et al. Practice 
patterns and long-term survival for early-stage rectal 
cancer. J Clin Oncol 2013;31:4276-82.
8. Nascimbeni R, Burgart LJ, Nivatvongs S, et al. Risk of 
lymph node metastasis in T1 carcinoma of the colon and 
rectum. Dis Colon Rectum 2002;45:200-6.
9. You YN, Baxter NN, Stewart A, et al. Is the increasing 
rate of local excision for stage I rectal cancer in the United 
States justified?: a nationwide cohort study from the 
National Cancer Database. Ann Surg 2007;245:726-33.
10. Glasgow SC. Advancing Dr Wong’s vision for evaluating 
rectal cancer. Dis Colon Rectum 2013;56:1325-6.
11. Garcia-Aguilar J, Mellgren A, Sirivongs P, et al. Local 
excision of rectal cancer without adjuvant therapy: a word 
of caution. Ann Surg 2000;231:345-51.
12. Nash GM, Weiser MR, Guillem JG, et al. Long-term 
survival after transanal excision of T1 rectal cancer. Dis 
Colon Rectum 2009;52:577-82.
13. Kikuchi R, Takano M, Takagi K, et al. Management of 
early invasive colorectal cancer. Risk of recurrence and 
clinical guidelines. Dis Colon Rectum 1995;38:1286-95.
14. Greenberg JA, Shibata D, Herndon JE 2nd, et al. Local 
excision of distal rectal cancer: an update of cancer and 
leukemia group B 8984. Dis Colon Rectum 2008;51:1185-
91; discussion 1191-4.
15. Hahnloser D, Wolff BG, Larson DW, et al. Immediate 
352 Heafner and Glasgow. Review of local excision for early (T1 and T2) rectal cancer
© Pioneer Bioscience Publishing Company. All rights reserved. J Gastrointest Oncol 2014;5(5):345-352www.thejgo.org
radical resection after local excision of rectal cancer: an 
oncologic compromise? Dis Colon Rectum 2005;48:429-37.
16. Doornebosch PG, Ferenschild FT, de Wilt JH, et al. 
Treatment of recurrence after transanal endoscopic 
microsurgery (TEM) for T1 rectal cancer. Dis Colon 
Rectum 2010;53:1234-9.
17. Gopaul D, Belliveau P, Vuong T, et al. Outcome of 
local excision of rectal carcinoma. Dis Colon Rectum 
2004;47:1780-8.
18. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. 
Preoperative radiotherapy combined with total mesorectal 
excision for resectable rectal cancer. N Engl J Med 
2001;345:638-46.
19. Sauer R, Becker H, Hohenberger W, et al. Preoperative 
versus postoperative chemoradiotherapy for rectal cancer. 
N Engl J Med 2004;351:1731-40.
20. Garcia-Aguilar J, Shi Q, Thomas CR Jr, et al. A phase II 
trial of neoadjuvant chemoradiation and local excision for 
T2N0 rectal cancer: preliminary results of the ACOSOG 
Z6041 trial. Ann Surg Oncol 2012;19:384-91.
21. Lezoche E, Baldarelli M, Lezoche G, et al. Randomized 
clinical trial of endoluminal locoregional resection versus 
laparoscopic total mesorectal excision for T2 rectal cancer 
after neoadjuvant therapy. Br J Surg 2012;99:1211-8.
22. Nair RM, Siegel EM, Chen DT, et al. Long-term results 
of transanal excision after neoadjuvant chemoradiation for 
T2 and T3 adenocarcinomas of the rectum. J Gastrointest 
Surg 2008;12:1797-805; discussion 1805-6.
23. Burghardt J, Buess G. Transanal endoscopic 
microsurgery (TEM): a new technique and development 
during a time period of 20 years. Surg Technol Int 
2005;14:131-7.
24. Christoforidis D, Cho HM, Dixon MR, et al. Transanal 
endoscopic microsurgery versus conventional transanal 
excision for patients with early rectal cancer. Ann Surg 
2009;249:776-82.
Cite this article as: Heafner TA, Glasgow SC. A critical review 
of the role of local excision in the treatment of early (T1 and 
T2) rectal tumors. J Gastrointest Oncol 2014;5(5):345-352. doi: 
10.3978/j.issn.2078-6891.2014.066
